Skip to main content
SpringerLink
Log in

Experimental Therapies in Cutaneous Lupus Erythematosus

  • Chapter
Cutaneous Lupus Erythematosus

  • 882 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alarcon-Segovia D, Tumlin J, Furie R, McKay J, Cardiel M, Linnik M, Hepburn B (2000) SLE trial shows fewer renal flares in LJP 394 treated patients with high-affinity antibodies to LJP 394: 90-05 trial results. Arthritis Rheum 43:S272

    Google Scholar 

  • Anolik J, Campbell D, Ritchlin C, Holyst M, Rosenfeld S, Sanz I, Young F, Felgar R, Kunkel L, Benyunes M, Grillo-Lopez A, Rosenblatt J, Looney RJ (2000) PhaseI/II open-label, dose-escalation trial of rituximab (Rituxan) in patients with SLE. Arthritis Rheum 43:2860

    Google Scholar 

  • Austin HA, Vaughan EM, Balow JE (2000) Lupus membranous nephropathy: randomized, controlled trial of prednisone, cyclosporine and cyclophosphamide. J Am Soc Nephrol 11:81A

    Article  Google Scholar 

  • Ballow M(1997) Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100:151–157

    Google Scholar 

  • Beissert S, Luger TA (1999) Future developments of antipsoriatic therapy. Dermatol Therapy 11:104–117

    Google Scholar 

  • Berner B, Scheel AK, Schettler V, Hummel KM, Reuss-Borst MA, Muller GA, Oestmann E, Leinenbach HP, Hepper M (2001) Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption. Ann Rheum Dis 60:898–899

    PubMed  Google Scholar 

  • Boehm IB, Boehm GA, Bauer R (1998) Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 18:59–62

    Article  PubMed  Google Scholar 

  • Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, Bonomo L (1997) Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 40:27–35

    PubMed  Google Scholar 

  • Callen JP (1982) Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 118:412–416

    Article  PubMed  Google Scholar 

  • Callen JP (2002) Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 16:245–264

    Article  PubMed  Google Scholar 

  • Carneiro JR, Sato EI (1999) Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 26:1275–1279

    PubMed  Google Scholar 

  • Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162

    Article  PubMed  Google Scholar 

  • Chandraratna RA (1997) Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 37:S12–S17

    PubMed  Google Scholar 

  • Chang DM, Lan JL, Lin HY, Taipei LSF, Taiwan T (2000) GL 701 (prasterone, dehydroepiandrosterone) significantly reduces flares in female patients with mild to moderate systemic lupus erythematosus (SLE). Arthritis Rheum 43:S241

    Google Scholar 

  • Charles PJ, Smeenk RJT, de Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2283–2390

    Article  PubMed  Google Scholar 

  • Conti F, Priori R, Alessandri C, Spinelli FR, Medda E, Valesini G (2000) Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. Lupus 9:676–680

    Article  PubMed  Google Scholar 

  • Dammacco F, Della Casa AO, Ferraccioli G, Racanelli V, Casatta L, Bartoli E (2000) Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res 30:67–73

    Article  PubMed  Google Scholar 

  • Daynes RA, Dudley DJ, Areano BA (1990) Regulation of murine lymphokine production in vivo. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 20:793–802

    PubMed  Google Scholar 

  • Delaporte E, Catteau B, Sabbagh N, Gosselin P, Breuillard F, Doutre MS, Broly F, Piette F, Bergoend H (1997) Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases. Ann Dermatol Venereol 124:151–156

    PubMed  Google Scholar 

  • Dequet CR, Wallace, DJ (2001) Novel therapies in the treatment of systemic lupus erythematosus. Curr Opin Investig Drugs 2:1045–1053

    PubMed  Google Scholar 

  • Diamond B, Bluestone J, Wofsy D (2001) The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum 44:1730–1735

    Article  PubMed  Google Scholar 

  • Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56:690–692

    PubMed  Google Scholar 

  • Dumont FJ (2002) IDEC-131. IDEC/Eisai. Curr Opin Investig Drugs 3:725–734

    PubMed  Google Scholar 

  • Edwards KR, Burke WA (1999) Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 41:1049–1050

    PubMed  Google Scholar 

  • Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, Sasayama S (1993) Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 64:471–475

    PubMed  Google Scholar 

  • Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S (2002) Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum 46:1408–1409

    Article  PubMed  Google Scholar 

  • Ferrario L, Bellone M, Bozzolo E, Baldissera E, Sabbadini MG (2000) Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology (Oxford) 39:218–220

    Article  Google Scholar 

  • Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265:1225–1227

    PubMed  Google Scholar 

  • Fleischmann M, Celerier P, Bernard P, Litoux P, Dreno B (1996) Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192:50–55

    PubMed  Google Scholar 

  • Frieling U, Luger TA (2002) Mycophenolate mofetile and leflunomide: promising compounds for the treatment of skin diseases. Clin Exp Dermatol 27:562–570

    Article  PubMed  Google Scholar 

  • Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Liebling MR, Hudson NP, Berner CM, Coutts S, de Haan HA (2001) Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 28:257–265

    PubMed  Google Scholar 

  • Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731–736

    Article  PubMed  Google Scholar 

  • Gaubitz M, Seidel M, Kummer S, Schotte H, Perniok A, Domschke W, Schneider, M (1998) Prospective randomized trial of two different immunoadsorbers in severesy stemic lupus erythematosus. J Autoimmun 11:495–501

    Article  PubMed  Google Scholar 

  • Geilen CC, Orfanos-Boeckel H, Offermann G, Orfanos CE (2000) Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses. Hautarzt 51:63–69

    Article  PubMed  Google Scholar 

  • Genereau T, Chosidow O, Danel C, Cherin P, Herson S (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124–1125

    Article  PubMed  Google Scholar 

  • Goyal S, Nousari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142–144

    Article  PubMed  Google Scholar 

  • Graninger M, Schmaldienst S, Derfler K, Graninger WB (2002) Immunoadsorption therapy (therasorb) in patients with severe lupus erythematosus. Acta Med Austriaca 29:26–29

    Article  PubMed  Google Scholar 

  • Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR (2000) Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9:241–251

    Article  PubMed  Google Scholar 

  • Haseley L, Wisnieski J, Denburg M, Michael-Grossman, AR, Ginzler EM, Gourley MF, Hoffman JH, Kimberly RP, Salmon JE (1997) Antibodies to C1q in systemic lupus erythematosus: Characteristics and relation to Fc-gamma RIIA alleles. Kidney Int 52:1375–1380

    PubMed  Google Scholar 

  • Hiepe F, Pfuller B, Wolbart K, Bruns A, Leinenbach HP, Hepper M, Schossler W, Otto V, (1999) C1q: a multifunctional ligand for a new immunoadsorption treatment. Ther Apher 3:246–251

    PubMed  Google Scholar 

  • Hsieh SC, Tsai CY, Sun KH, Tsai YY, Tsai ST, Han SH, Yu HS, Yu CL (1995) Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Br J Rheumatol 34:107–112

    PubMed  Google Scholar 

  • Huddlestone JR, Merigan TC Jr, Oldstone MB (1979) Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 282:417–419

    Article  PubMed  Google Scholar 

  • Jungers P, Nahoul K, Pelissier C, Dougados M, Tron F, Bach JF (1982) Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum 25:454–457

    PubMed  Google Scholar 

  • Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL (1997) Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 37:445–449

    PubMed  Google Scholar 

  • Kuhn A, Specker C, Ruzicka T, Lehmann P (2002) Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 46:600–603

    Article  PubMed  Google Scholar 

  • Lafferty TE, Smith JB, Schuster SJ, DeHoratius RJ (1997) Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 40:775–778

    PubMed  Google Scholar 

  • Lagrange S, Piette JC, Becherel PA, Cacoub P, Frances C (1998) Sulfasalazine in the treatment of cutaneous lupus erythematosus: open trial in six cases. Lupus 7:21

    Google Scholar 

  • Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, Poprac P, Langevitz P, Fabbrizzi F, Shoenfeld Y (2000) Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29:321–327

    Article  PubMed  Google Scholar 

  • Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 326:1373–1379

    PubMed  Google Scholar 

  • Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putativerole in pathogenesis. J Immunol 147:117–123

    PubMed  Google Scholar 

  • Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J, Galanaud P, Emilie D (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790–1800

    Article  PubMed  Google Scholar 

  • Luger T (2001) Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 11:343-347

    Google Scholar 

  • Manger K, Kalden JR, Manger B (1996) Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J R heumatol 35:669–675

    Google Scholar 

  • Matis LA, Rollins SA (1995) Complement-specific antibodies: designing novel anti-inflammatories. Nat Med 1:839–842

    Article  PubMed  Google Scholar 

  • McMurray RW (2001) Nonstandard and adjunctive medical therapies for systemic lupus erythematosus. Arthritis Rheum 45:86–100

    Article  PubMed  Google Scholar 

  • McNeely PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Linnik MD (2001) Pre-treatmentaffinity for LIP 394 influences pharmacodynamic response in lupus patients. Lupus 10:526–532

    Article  PubMed  Google Scholar 

  • Mease PJ, Ginzler EM, Gluck OS, Schiff MH, Schmeer P, Gurwith M, Schwarz KE (2000) Improvementin bone mineral density in steroid-treated patients during treatment with GL 701 (prasterone, DHEA). Arthritis Rheum 43(Suppl):206

    Article  PubMed  Google Scholar 

  • Melez KA, Boegel WA, Steinberg AD (1980) Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different ages. Arthritis Rheum 23:41–47

    PubMed  Google Scholar 

  • Morton SJ, Powell RJ (2000) An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis 59:487–489

    Article  PubMed  Google Scholar 

  • Moxley G, Ruddy S (1997) Immune complexes and complement. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 232–235

    Google Scholar 

  • Neuwelt CM, Al-Baude HA, Webb RL (1995) Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus. Am J Med 98:32–41

    Article  PubMed  Google Scholar 

  • Nicolas JF, Thivolet J, Kanitakis J, Lyonnet S (1990) Response of discoid and subacute cutaneous lupus erythematosus torecombinant interferon alpha 2a. J Invest Dermatol 95:142S–145S

    Article  PubMed  Google Scholar 

  • Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M (2001) A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44:S47–S57

    Article  PubMed  Google Scholar 

  • Petera P, Manger B, Manger K, Rosenburg R, Smolen JS, Kalden JR (2000) A pilot study of leflunomide in systemic lupus erythematosus (SLE). Arthritis Rheum 43:S241

    Google Scholar 

  • Petri M (2001) High dose Arava in lupus (HAIL). Arthritis Rheum 44:S280

    Google Scholar 

  • Pfuller B, Wolbart K, Claunitzer A et al. (1998) Successful treatment of systemic lupus erythematosus by C1q-immunoadsorption. Arthritis Rheum 41:S110

    Article  Google Scholar 

  • Pisetsky DS (2000) Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 43:2381–2382

    Article  PubMed  Google Scholar 

  • Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G (1996) Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 34:244–252

    PubMed  Google Scholar 

  • Ramanujam M, Wang X, Ghosh SS, Huang W, Akkerman A, Roy-Chowdhury I, Davidson A (2002) Treatment of murine SLE using a double expressing CTLA4-Ig/ICOS-Ig adenovirus. Arthritis Rheum 46:S226

    Google Scholar 

  • Rappersberger LE, Komar M, Ebelin ME, Scott G, Bueche M, Burtin P, Wolff K (2000) Oral SDZ ASM981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis. J Invest Dermatol 114:776

    Google Scholar 

  • Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480–483

    Article  PubMed  Google Scholar 

  • Riethmuller G, Rieber EP, Kiefersauer S, Prinz J, van der LP Meiser B, Breedveld F, Eisenburg J, Kruger K, Deusch K (1992) From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev 129:81–104

    PubMed  Google Scholar 

  • Rodriguez-Castellanos MA, Rubio JB, Gómez JFB, Mendoza AG (1995) Phenytoin in the Treatment of Discoid Lupus Erythematosus. Arch Dermatol 131:620–621

    Article  Google Scholar 

  • Ronnblom LE, Alm G, Vberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227:207–210

    PubMed  Google Scholar 

  • Rudnicka L, Szymanska E, Walecka I, Slowinska M (2000) Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. A report of three cases. Dermatology 200:29–131

    Article  Google Scholar 

  • Rutter A, Luger TA (2002) Intravenous immunoglobulin: An emerging treatment for immunemediated skin diseases. Curr Opin Investig Drugs 3:713–719

    PubMed  Google Scholar 

  • Sauder DN, Wong D, Laskin C (1993) Epidermal cytokines in murine lupus. J Invest Dermatol 100:42S–46S

    Article  PubMed  Google Scholar 

  • Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147:174–178

    Article  PubMed  Google Scholar 

  • Schattner A (1988) Interferons and autoimmunity. Am J Med Sci 295:532–544

    PubMed  Google Scholar 

  • Schopf RE (2001) IDEC-114 (IDEC). Curr Opin Ivestig Drugs 2:635–638

    Google Scholar 

  • Shou-Nee S, Fang FS, Yumei W (1987) Serum interferon in systemic lupus erythematosus. Br J Dermatol 117:155–159

    PubMed  Google Scholar 

  • Solsky MA, Wallace DJ (2002) New therapies in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 16:293–312

    Article  PubMed  Google Scholar 

  • Strand V (2000) New therapies for systemic lupus erythematosus. Rheum Dis Clin North Am 26:389–405

    PubMed  Google Scholar 

  • Sturgess AD, Evans DT, Mackay IR, Riglar A (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11–14

    PubMed  Google Scholar 

  • Tebbe B, Lauy M, Gollnick H (1992) Therapy of cutaneous lupus erythematosus with recombinant interferon alpha-2a. Eur J Dermatol 2:253–255

    Google Scholar 

  • Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ayus JC (1979) Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet 2:824–827

    Article  PubMed  Google Scholar 

  • Theofilopoulos AN, Drummer W, Kono DH (2001) T cell homeostasis and systemic autoimmunity. J Clin Invest 108:335–340

    Article  PubMed  Google Scholar 

  • Tomi NS, Luger TA (2003) The treatment of atopic dermatitis with topical immunomodulators. Clinics Dermatol 21:215–224

    Article  Google Scholar 

  • Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK (2000) Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356:701–707

    Article  PubMed  Google Scholar 

  • Viertel A, Weidmann E, Wigand R, Geiger H, Mondorf UF (2000) Treatment of severe systemic lupus erythematosus with immunoadsorption and intravenous immunoglobulins. Intensive Care Med 26:823–824

    Article  PubMed  Google Scholar 

  • Vigano G, Gotti E, Casiraghi F, Noris M, Taddei I, Dionisio P, Remuzzi G (1995) Bindarit reduces urinary albumin excretion (UAB) and urinary interleukin 6 (IL-6) in patients with proliferative lupus nephritis. J Am Soc Nephrol 6:434

    Google Scholar 

  • Walker SL, Kirby B, Chalmers RJ (2002) The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 147:405

    Article  PubMed  Google Scholar 

  • Wallace DJ (2001a) Apheresis for lupus erythematosus: state of the art. Lupus 10:193–196

    Article  PubMed  Google Scholar 

  • Wallace DJ (2001b) Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs 10:111–117

    Article  PubMed  Google Scholar 

  • Walport MJ, Davies KA, Botto M (1998) C1q and systemic lupus erythematosus. Immunobiology 199:265–285

    PubMed  Google Scholar 

  • Wu WM, Suen JL, Lin BF, Chiang BL (2000) Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology 100:110–118

    Article  PubMed  Google Scholar 

  • Yin Z, Bahtiyar G, Lanzhen L (2000) IL-10 down-modulates murine lupus. Arthritis Rheum 43:S438

    Google Scholar 

  • Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F (2002) Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 12:50–52

    PubMed  Google Scholar 

  • Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, Pinza M, Bertani T, Remuzzi G (1998) Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 53:726–734

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Stefan W. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas A. Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hautklinik, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Annegret Kuhn  & Thomas Ruzicka  & 

  2. HELIOS Klinikum Wuppertal Klinik für Dermatologie, Allergologie und Umweltmedizin, Universitätsklinikum Witten-Herdecke, Arrenbergerstraße 20, 42117, Wuppertal, Germany

    Percy Lehmann

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Schneider, S.W., Luger, T.A. (2005). Experimental Therapies in Cutaneous Lupus Erythematosus. In: Kuhn, A., Lehmann, P., Ruzicka, T. (eds) Cutaneous Lupus Erythematosus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26581-3_30

Download citation

  • DOI: https://doi.org/10.1007/3-540-26581-3_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-44266-0

  • Online ISBN: 978-3-540-26581-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation